MedTrace Logo

Drug-drug Interaction Study of KL1333 in Healthy Subjects

NCT04643249 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-10-20

No results posted yet for this study

Summary

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Conditions

Interventions

DRUG

KL1333

Tablet

DRUG

Flurbiprofen

Tablet

DRUG

Dextromethorphan

Syrap

DRUG

Bupropion

Tablet

DRUG

Midazolam injection

solution for injection

DRUG

Omeprazole

Capsule

DRUG

Caffeine

Tablet or capsule

DRUG

Repaglinide

Tablet

Sponsors & Collaborators

  • Abliva AB

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-10
Primary Completion
2020-12-17
Completion
2020-12-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04643249 on ClinicalTrials.gov